Actuate Therapeutics (NASDAQ:ACTU) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Actuate Therapeutics (NASDAQ:ACTU) from a sell rating to a hold rating in a report published on Saturday.

Several other research firms have also recently issued reports on ACTU. Weiss Ratings reissued a “sell (e+)” rating on shares of Actuate Therapeutics in a research note on Monday, December 29th. HC Wainwright reiterated a “buy” rating and issued a $20.00 price objective on shares of Actuate Therapeutics in a report on Wednesday, November 19th. Three analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Actuate Therapeutics has an average rating of “Moderate Buy” and an average price target of $20.33.

Actuate Therapeutics Stock Up 2.1%

Shares of Actuate Therapeutics stock opened at $4.33 on Friday. The firm has a market cap of $100.63 million, a PE ratio of -4.98 and a beta of -0.15. Actuate Therapeutics has a 12-month low of $4.04 and a 12-month high of $11.99. The company’s fifty day simple moving average is $5.79 and its two-hundred day simple moving average is $6.74.

Insider Buying and Selling at Actuate Therapeutics

In other news, Director Todd S. Thomson sold 280,000 shares of the stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $5.80, for a total value of $1,624,000.00. Following the completion of the transaction, the director owned 904,795 shares of the company’s stock, valued at approximately $5,247,811. This represents a 23.63% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 69.34% of the company’s stock.

Institutional Investors Weigh In On Actuate Therapeutics

Several hedge funds have recently made changes to their positions in the company. ABS Direct Equity Fund LLC bought a new position in Actuate Therapeutics in the fourth quarter worth $40,000. Deutsche Bank AG grew its position in shares of Actuate Therapeutics by 640.0% in the 4th quarter. Deutsche Bank AG now owns 9,309 shares of the company’s stock worth $57,000 after buying an additional 8,051 shares during the period. Sfmg LLC increased its stake in shares of Actuate Therapeutics by 32.3% in the 2nd quarter. Sfmg LLC now owns 14,550 shares of the company’s stock worth $89,000 after acquiring an additional 3,550 shares in the last quarter. Barclays PLC lifted its position in Actuate Therapeutics by 68.6% during the 4th quarter. Barclays PLC now owns 14,946 shares of the company’s stock valued at $91,000 after acquiring an additional 6,081 shares during the period. Finally, Bank of America Corp DE boosted its stake in Actuate Therapeutics by 61,068.0% during the second quarter. Bank of America Corp DE now owns 15,292 shares of the company’s stock worth $93,000 after acquiring an additional 15,267 shares in the last quarter.

Actuate Therapeutics Company Profile

Actuate Therapeutics (NASDAQ: ACTU) is a clinical-stage oncology company focused on the discovery and development of targeted therapies designed to address key drivers of tumor growth and survival. Headquartered in South San Francisco, California, the company applies a precision medicine approach to identify novel molecular targets and develop small-molecule agents that have the potential to improve outcomes for patients with difficult-to-treat cancers.

The company’s lead asset, atuveciclib, is a selective, oral CDK9 inhibitor being evaluated in a Phase 1 clinical trial for patients with acute myeloid leukemia and advanced solid tumors.